FDA placed a clinical hold on Phase 2/3 trials for SK Biopharm on September 1, 2026.
1 report, 1 independent
Updated Sep 1
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
FDA placed a clinical hold on Phase 2/3 trials for SK Biopharm on September 1, 2026.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
Related events
- FDA issued a partial clinical hold on trials involving Biohaven Ltd. on September 11, 2026.
- SynAct Pharma AB is seeking discussion with the FDA regarding the design of its Phase 3 clinical trials.
- Nkarta is seeking protocol amendments for its clinical trials under the FDA.
- TELIX Pharmaceuticals is conducting Phase 3 trials and seeking alignment on the New Drug Application pathway with the FDA.
- The FDA granted Safe to Proceed for the Pivotal Phase 3 study of Vivace Therapeutics, Inc.